

(51) International Patent Classification:
C07D 305/14 (2006.01)(21) International Application Number:
PCT/EP2014/071596(22) International Filing Date:
9 October 2014 (09.10.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13189944.5 23 October 2013 (23.10.2013) EP

(71) Applicant: INDENA S.p.A. [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(72) Inventors: CABRI, Walter; c/o INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). CICERI, Daniele; c/o INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). DOMENIGHINI, Luca; c/o INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). GAMBINI, Andrea; c/o INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT). PETERLONGO, Federico; c/o INDENA S.p.A., Viale Ortles, 12, I-20139 Milano (IT).

(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Plinio, 63, I-20129 Milano (IT).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE SOLVATE FORMS OF CABAZITAXEL

(57) Abstract: The present invention relates to new crystalline forms of Cabazitaxel of formula (I). Specifically, the present invention provides four new crystalline solvate forms of Cabazitaxel, designated as form S2 (solvate with 2-methyltetrahydrofuran), form S4 (solvate with *tert*-butyl acetate), form S5 (solvate with dimethylcarbonate) and form S6 (solvate with N-methyl-2-pyrrolidinone). A further object of the present invention are processes for the preparation of the above mentioned crystalline forms. The crystalline solvate forms of the invention are especially useful for the preparation of Cabazitaxel, Cabazitaxel salts, and polymorphic forms thereof.